Drug Profile
Adalimumab biosimilar - mAbxience
Latest Information Update: 13 Sep 2023
Price :
$50
*
At a glance
- Originator mAbxience
- Class Anti-inflammatories; Anti-TNF monoclonal antibodies; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Hepatoprotectants; Immunotherapies; Nootropics; Skin disorder therapies
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Rheumatoid arthritis in Spain (SC) (mAbxience pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Spain (SC, Injection)
- 02 Aug 2016 Preclinical trials in Rheumatoid arthritis in Spain (SC)